Prohost Biotech – Exclusive Biotech Research – A Comprehensive Resource for Biotech News

Amgen’s product Amgevita, a biosimilar to adalimumab, will be launched in the European market today.

October 16, 2018 0

Amgen (AMGN) announced that AmgevitaTM, a biosimilar to adalimumab, will launch in markets across Europe beginning on October 16, 2018. According to Amgen’s press release, AmgevitaTM is the first adalimumab biosimilar to be approved by the European Commission (EC). The EC approval is based on analytical, pharmacokinetic and clinical data, including results from two Phase 3 confirmatory studies of the product for moderate-to-severe plaque psoriasis and …

$Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated thyroid cancer (DTC) patients$

Exelixis initiates phase 3 trial with Cabometyx in radioiodine-refractory differentiated...

The FDA granted Paratek two important product approvals. One is...

Antisense investigational product demonstrates successful results treating a life-threatening disease...

The medical news of the year comes at the hands...

Exelixis: Health Canada approves Cabometyx in advanced renal cell carcinoma

Viking Therapeutics: VK2809 scores impressive results in non-alcoholic fatty liver...

Argenx’s product, Efgartigimod, demonstrates positive results in primary immune thrombocytopenia

Gilead Sciences: In pursuit of cures for intractable diseases

Amgen and AstraZeneca have in hand a very much needed...

Gilead and Galapagos have good news for patients with severely...

RegenxBio has good news

PTC Therapeutics now with a wealthier pipeline

When all the prophets are taken by surprise

Why Celyad’s stock gained $2.30 today

Aerie’s successful new confirmatory study for Rhopressa® was a necessity

Regeneron’s and Bluebird Bio’s collaboration is meant to create advanced...

A new European approval for Bristol-Myers’ immunotherapy opdivo. The future...

The EU CHMP Recommends Approving Alnylam’s RNAi Therapeutic, ONPATTRO™

Novartis Pleased the Market with Its Q2 Financial Results and...

Today’s Highlights

Why Portola’s stock decline

October 17, 2018 0

Why Portola’s Stock Decline Everybody interested in Portola (PTLA) knows by now that this firm has managed …

Why VTV Therapeutics’ stock added over 48% to its price before trading hours today

October 17, 2018 0

VTV Therapeutics’ (VTVT) stock price added over 48% before trading hours today. The news that some …

After being approved for Eczema, Regeneron’s and Sanofi’s product, Dupixent, succeeded in treating chronic rhinosinusitis, nasal polyps and asthma.

October 16, 2018 0

In two pivotal Phase 3 placebo-controlled trials Regeneron Pharmaceuticals’ (REGN) and Sanofi’s (SNY) drug, Dupixent® (dupilumab), demonstrated a …

Spark Therapeutics: An encouraging attempt to dethrone enzyme replacement as the standard of care treatment for Pompe Disease.

October 9, 2018 0

On Saturday, October 6, 2018, Spark Therapeutics (ONCE) presented positive data from a preclinical trial with SPK-3006 …

Today’s Highlighted news is from …

October 5, 2018 0

Today, Prohost is highlighting news that could be transformative for a clinical-stage immunotherapy firm. The firm …

PTC Therapeutics: Solid data from its oral product Risdiplam in spinal muscular atrophy

October 4, 2018 0

PTC Therapeutics’ (PTCT) product Risdiplam demonstrated safety and tolerability at all the doses used in the …

Seattle Genetics and Takeda Pharmaceutical Limited announced a successful trial on mature T-Cell lymphoma

October 1, 2018 0

Seattle Genetics (SGEN) and Takeda Pharmaceutical Limited (TKPYY) announced results from Phase 3 ECHELON-2 clinical trial evaluating Adcetris …

AstraZeneca: Advancing and improving Stage III lung cancer treatments

September 26, 2018 0

Stage III (locally-advanced) NSCLC is commonly divided into three sub-categories: IIIA, IIIB and IIIC, defined by …

A Bayer testing of Compugen’s checkpoint protein in human trial boosted our expectations for Compugen’s resurrection

September 21, 2018 0

Compugen Again On Sept 10, 2018, we posted in The Week in Review #28 news we found …

About Portola’s appointment of a new president. Read Also: Why CRISPR lost $2.90 today

September 20, 2018 0

Portola Pharmaceuticals Appoints Scott Garland as President and Chief Executive Officer, Effective October 8, 2018. Portola (PTLA) appointed …

The Week in Review

Outperformance, underperformance and volatility

October 2, 2018 0

The Week in Review #31 IN THE DEPARTED WEEK NOVEL MIGRAINE DRUGS ARE APPROVED ELI LILLY …

Three important news

September 25, 2018 0

The Week in Review #30 FROM THE DEPARTED WEEK In the past week, we came across …

What is looking good in the aggressive portfolio

September 10, 2018 0

The Week in Review #29 PROHOST AGGRESSIVE PORTFOLIO - The aggressive portfolio hosts biotech firms with …

Outperforming, favorite, and undervalued biotech firms

September 3, 2018 0

The Week in Review #28 The approval of revolutionary products created by biotech firms with solid …

Bombarding future treatment approaches

August 15, 2018 0

The Week in Review #27 PRIORITY TOPICS: CRISPR GENE EDITING, GENETIC ENGINEERING & ANTISENSE TECHNOLOGY The choice of these …

Stories about research, clinical trials results and an FDA ruling

July 9, 2018 0

The Week in Review #26 IN THE BIOTECH WORLD - RESEARCH - IMPROVING CRISPR GENE EDITING The problem …

Finding reasons for underperforming stocks

July 2, 2018 0

The Week in Review #25 When Stocks Plummet for No Relevant Reasons Sometimes investors need to know …

Our outperforming firms and more

June 25, 2018 0

The Week in Review #24 Biotech Stocks’ Performances, Products on the Move and Biotech Research Biotechnology …

Good news, bad news & comebacks. Some ASCO results too

June 19, 2018 0

The Week in Review #23 ASCO 2018 - Small publicly-traded oncology biotech firms, large oncology biotech …

An Approval & a Rejection. Both Considered Good News. A Small Firm is Added to the Prohost Portfolio

May 7, 2018 0

The Week in Review #22 What Went Right or Wrong in the Biotech Sector During the …

Prohost Letters

Following the Stars. Less Science and More Logic

October 14, 2018 0

Prohost Letter #424 Following the Stars Less Science and More Logic We reiterate that while a …

Victims of fear and misunderstanding

August 1, 2018 0

ProhostLetter #423 TOMORROW’S THERAPEUTICS TODAY For a more or less fair evaluation of biotechnology and pharmaceutical …

New stock selection and re-evaluation

June 8, 2018 0

Prohost Letter #422 SUMMARY OF THE PAST ISSUE ARTICLE - REVISITING PROMISING FIRMS (PART1) - The …

Revisiting Biotech Companies We Highlighted

May 25, 2018 0

Prohost Letter #421 PRIVATE LESSONS - Stock prices of publicly-traded biotech companies oscillate for the same …

Real Breakthroughs

April 17, 2018 0

Prohost Letter #420 REAL BREAKTHROUGHS - One Has Already Been Used and the Other Has Extraordinary …

The Prohost Portfolio: Updating the Stock Targets

March 15, 2018 0

Prohost Letter #419 RE-EVALUATION ONLY - The Prohost Portfolio comprises biotechnology and biopharmaceutical companies, that we …

Observing Queer Stories

March 2, 2018 0

Prohost Letter #418 Observing Queer Stories PORTOLA - Portola (PTLA) has been granted approval of an …

Private Lessons and More

February 9, 2018 0

Prohost Letter #417 Private Lessons - These lessons are overdue and we had to do this …

The Year in Review Part 2

January 10, 2018 0

Prohost Letter #416 Part 2 2017 - A YEAR OF BREAKTHROUGH TECHNOLOGIES, BREAKTHROUGH PRODUCTS, IMPROVEMENTS ON …

The Year in Review Part 1

December 31, 2017 0

Prohost Letter #416 Part 1 The Year In Review - 2017 Unheard of Programs - AN …